Sarah J B Gramling

BRG1 and BRM loss selectively impacts RB and P53, respectively: BRG1 and BRM have differential functions in vivo

D. Reisman, Li Lu, S. Gramling, 2016, Oncoscience.

Association of two BRM promoter polymorphisms with head and neck squamous cell carcinoma risk.

R. Gilbert, B. O'Sullivan, A. Azad, 2013, Carcinogenesis.

Two novel BRM insertion promoter sequence variants are associated with loss of BRM expression and lung cancer risk

M. Tsao, F. Shepherd, A. Azad, 2011, Oncogene.

Flavonoids from each of the six structural groups reactivate BRM, a possible cofactor for the anticancer effects of flavonoids.

D. Reisman, B. Kahali, A. Aponick, 2014, Carcinogenesis.

Identifying targets for the restoration and reactivation of BRM

D. Reisman, B. Kahali, S. Marquez, 2014, Oncogene.

Pharmacologic reversal of epigenetic silencing of the anticancer protein BRM: a novel targeted treatment strategy

D. Reisman, C. Rogers, S. Gramling, 2011, Oncogene.